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Interleukin-33 enhances programmed oncosis of
ST2L-positive low-metastatic cells in the tumour
microenvironment of lung cancer
M Akimoto1, J-I Hayashi2, S Nakae3, H Saito4 and K Takenaga*,1
The proinflammatory interleukin-33 (IL-33) binds to its receptor ST2L on the surface of immune cells and stimulates the production
of Th2 cytokines; however, the effects of IL-33 on tumour cells are poorly understood. Here we show that ST2 was significantly
downregulated in human lung cancer tissues and cells compared with normal lung tissues and cells. IL-33 expression was also
inversely correlated with the stages of human lung cancers. In accordance with this finding, low-metastatic cells but not high-
metastatic cells derived from Lewis lung carcinoma expressed functional ST2L. IL-33 was abundantly present in the tumours
established by the low-metastatic cells compared with those formed by the high-metastatic cells. Although the low-metastatic cells
scarcely expressed IL-33 in vitro, these cells did expry 6ess this molecule in vivo, likely due to stimulation by intratumoural IL-1β
and IL-33. Importantly, IL-33 enhanced the cell death of ST2L-positive low-metastatic cells, but not of ST2L-negative high-
metastatic cells, under glucose-depleted, glutamine-depleted and hypoxic conditions through p38 MAPK and mTOR activation,
and in a mitochondria-dependent manner. The cell death was characterised by cytoplasmic blisters and karyolysis, which are
unique morphological features of oncosis. Inevitably, the low-metastatic cells, but not of the high-metastatic cells, grew faster in
IL-33− /− mice than in wild-type mice. Furthermore, IL-33 selected for the ST2L-positive, oncosis-resistant high-metastatic cells
under conditions mimicking the tumour microenvironment. These data suggest that IL-33 enhances lung cancer progression by
selecting for more malignant cells in the tumour microenvironment.
Cell Death and Disease (2016) 7, e2057; doi:10.1038/cddis.2015.418; published online 21 January 2016
Interleukin-33 (IL-33), a member of the IL-1 cytokine family, is a
natural ligand for the IL-33 receptor, which is a heterodimer
composed of ST2L and the IL-1 receptor accessory protein
(IL-1RAcP).1–3 IL-33 is primarily expressed in epithelial cells and
endothelial cells as a proinflammatory cytokine.4,5 IL-33 is usually
localised in the cell nucleus as an alarmin that signals to local
immune cells in response to tissue damage caused by injury,
necrosis or exposure to pathogens.6–8 IL-33 polarises naive
T cells to produce Th2-associated cytokines, it strongly induces
proinflammatory cytokine and chemokine production by mast
cells and eosinophils, and it stimulates the polarisation of
alternatively activated M2 macrophages.9,10 Thus, IL-33 has an
important role in Th2 immunity andTh2-related diseases, such as
asthma, atopic dermatitis and anaphylaxis.6,11–14 ST2L is
expressed on the cell surface of Th2 cells, but not of Th1 cells,
and on the cell surface of other immune-related cells includingNK
and NKT cells.8,15–17 Human bronchial epithelial cells and rat
alveolar type-II cells, which can be the cellular origins of
bronchoalveolar carcinomas and adenocarcinomas, respectively,
human lung microvascular endothelial cells and human intestinal
epithelial cells, are also reported to express ST2L.18–22
IL-33 binding to ST2L/IL-1RAcP initiates the recruitment of
the myeloid differentiation primary response 88 (MyD88)/IL-1
receptor-associated kinase 4/IRAK1/tumour necrosis factor
(TNF) receptor-associated factor 6 module and then activates
tumour growth factor-β-activated kinase 1. This activation
stimulates the activation of nuclear factor-κB (NF-κB),
mitogen-activated protein kinase p38 (p38 MAPK), c-JUN
N-terminal kinases (JNK) and, in parallel, extracellularly
regulated kinases (p44/42 MAPK), leading to the production
of the inflammatory mediators.23–25
A relationship between the IL-33/ST2L axis and cancer is
beginning to be recognised. IL-33 enhances murine breast
cancer growth and metastasis by increasing the intratumoural
accumulation of immunosuppressive and innate lymphoid
cells.26 Higher serum levels of IL-33 were found to be a worse
prognostic marker in gastric cancer and in non-small-cell lung
carcinoma patients.27,28 From these observations, IL-33
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appears to promote tumour malignancy by modulating
Th2-type immunity.
Whether the tumour cells express functional ST2L remains
unknown. If these cells do express functional ST2L, then IL-33
in the tumour microenvironment might directly affect their
behaviour. In this study, we sought ST2L-positive tumour
cells and eventually found that low-metastatic, but not
high-metastatic, Lewis lung carcinoma (3LL) cells expressed
functional ST2L. We demonstrate that IL-33 induced
programmed oncosis of the ST2L-positive low-metastatic
cells, under conditions mimicking the tumour microenviron-
ment, thereby allowing the outgrowth of the ST2L-negative
high-metastatic cells in equal mixtures, suggesting a role for
IL-33 in the malignant progression of lung cancers.
Results
ST2 and IL-33 expression in human lung cancers and
pulmonary alveolar cells. We searched the Oncomine
database for ST2 (IL1RL1) and IL-33 expression levels in
lung cancer tissues and in adjacent normal lung tissues. ST2
mRNA was found to be significantly downregulated in lung
cancers irrespective of histological types (Hou and other data
sets;29–33 Figure 1A; Supplementary Figure 1). Survival
analysis in PrognoScan database34 also revealed that the
ST2 expression level was inversely correlated with relapse-
free survival and overall survival (Okayama data set,
GSE31210; Figure 1B). Likewise, IL-33 mRNA was signifi-
cantly downregulated in lung cancers, inversely correlating
with the malignancy index (tumour stage, recurrence and
overall survival; Okayama and other data sets)29–31,33,35
(Figures 1c and d; Supplementary Figure 2). To investigate
whether these differences were also observed at the cellular
level, we examined the expression of ST2-related molecules
in human pulmonary alveolar epithelial cells (HPAEpiCs)
that were positive for the alveolar type-II cell marker
surfactant protein C (Figure 1E) and in human lung
adenocarcinoma A549 cells. IL-33 was detected in the nuclei
of HPAEpiCs (Figure 1E), indicating its role as an alarmin in
these cells. qRT-PCR analysis revealed that ST2L, sST2, a
secreted soluble ST2 that acts as a decoy receptor for IL-33,
IL-1RAcP, MyD88 and IL-33 were expressed in HPAEpiCs,
whereas those genes were significantly downregulated in
A549 cells (Figure 1F). Next, we examined the expression
levels of these genes in various established human lung
cancer cell lines. Among 10 cell lines, only PC-14
adenocarcinoma cells expressed a substantial amount of
ST2L mRNA. However, these cells did not express IL-1RAcP
mRNA (Figure 1G), indicating that this receptor is non-
functional. Thus, none of the human lung cell lines that have
been examined thus far expressed functional ST2L. To
understand the role of the IL-33/ST2L axis in lung
cancers, we sought to identify lung cancer cells expressing
functional ST2L. We found that the low-metastatic cells (P29
and P34) derived from 3LL expressed ST2L, whereas the
high-metastatic cells (D6 and A11) only slightly expressed
ST2L (Figures 2a and b). P29 and P34 cells also expressed
IL-1RAcP and MyD88 (Figures 2a and b). All 3LL cell lines
expressed very little IL-33 (Supplementary Figure 3).
Recombinant IL-33 (rIL-33) rapidly activated p38
MAPK, JNK and IκB-α but not p44/42 MAPK in P29 cells
(Figure 2c) but not in A11 cells (Supplementary Figure 4).
rIL-33 also induced the expression of nitric oxide synthase 2
(NOS2) and cyclooxygenase-2 (COX2) mRNAs but not of
IL-1β and IL-6 mRNA, all of which are NF-κB target
genes, in P29 cells (Figure 2d). Thus, these results clearly
indicate the functionality of ST2L in P29 cells. However,
rIL-33 did not affect either the cell growth or the invasive-
ness of P29 cells under standard culture conditions
(Figures 2e and f).
IL-33-presenting cells in 3LL tumours. To examine
whether IL-33 is present in 3LL tumour tissues, we first
quantified the amount of IL-33 protein in lysates of P29 and
A11 tumours established in B6-wild-type (B6) mice and in
P29 tumours in IL-33-deficient (IL-33− /−) mice. The results
showed that a higher amount of IL-33 protein was present in
P29 tumours than in A11 tumours, which exhibited rather low
levels compared with that in the lung (Figure 3a). Unexpect-
edly, P29 tumours in IL-33− /− mice did express IL-33 protein
irrespective of that P29 cells hardly express IL-33 in vitro,
although the amount was lower than that in B6 mice
(Figure 3b). Supporting this result, immunohistochemical
analysis of P29 tumours in both B6 and IL-33− /− mice
demonstrated that scattered cells mostly had nuclear IL-33
staining, whereas some cells had both nuclear and cyto-
plasmic staining (Figure 3c). The IL-33 immunofluorescence
was stronger, and the number of the IL-33+ cells per mm2
was larger in P29 tumours in B6 mice than those in IL-33− /−
mice (Figures 3c and d), but clear immunofluorescence
signals was absent in A11 tumours (Figure 3c). F4/80+
tumour-associated macrophages (TAMs), α-smooth muscle
actin (αSMA)+ cancer-associated fibroblasts (CAFs), CD3+
lymphocytes and CD31+ tumour endothelial cells were
negative for IL-33 (Supplementary Figure 5a), and IL-33
was detected in some EGFP-positive cells in EGFP-P29
tumours (Supplementary Figure 5b). On the basis of these
observations, we concluded that some but not all P29 cells in
the tumours express IL-33. We assumed that IL-33 itself and
some types of IL-33-related factors were involved in inducing
IL-33 in P29 cells in vivo and tested the effects of
several cytokines, including IL-33, IL-1β, IL-4, IL-6, inter-
feron-γ (IFN-γ), TNF-α and tumour necrosis factor-related
apoptosis-inducing ligand (TRAIL). The results showed that
IL-1β potently induced IL-33 mRNA expression in P29 cells in
a time- and dose-dependent manner (Figures 3e and f).
IL-33, IL-4, IL-6 and TRAIL also slightly induced IL-33 mRNA
expression (Figure 3e; Supplementary Figure 6). None
of the cytokines induced IL-33 expression in A11 cells
(Figure 3e). IL-1β was abundant in P29 tumours at the
mRNA level, particularly in the peripheral region, in B6 mice
compared with those tumours in IL-33− /− mice, and IL-4, IL-6
and TRAIL expression was quite low in both types of tumours
(Figure 3g). We therefore consider that intratumoural IL-1β
and IL-33 is primarily responsible for IL-33 expression in P29
tumours. However, at present, we cannot explain the reason
why not all P29 cells in the tumours expressed IL-33.
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rIL-33 enhances the death of the low-metastatic 3LL cells
under nutrient-depleted and hypoxic/anoxic conditions.
Given that the less malignant 3LL cells express functional
ST2L and that IL-33 is highly expressed in less malignant
tumours, coinciding well with the gene expression profiles in
human lung adenocarcinomas (Figure 1A; Supplementary
Figures 1 and 2), we hypothesised that IL-33 might affect
the phenotypes of cells under conditions that mimic the
tumour microenvironment, such as nutrient depletion and
hypoxia. Surprisingly, we found that rIL-33 enhanced the
death of P29 and P34 cells, but not of D6 and A11 cells, in
low-glucose (0.1 g/l glucose) medium (GlucL) in a dose- and
time-dependent manner (Figures 4a and c) and in medium
containing various concentrations of glucose (0–0.4 g/l;
Figure 4d), as assessed by the trypan blue dye exclusion
test, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium
bromide (MTT) and clonogenic assays (Figure 4e,
Supplementary Figure 7). rIL-33 also enhanced the death
of P29 and P34 cells, but not of D6 and A11 cells, under
glutamine-depleted (Gln−; Figures 4f and g) and hypoxic/
anoxic conditions (Figure 4h), but not in serum-depleted
medium (Figure 4i).
To confirm whether the death-enhancing effect of IL-33 is
mediated by ST2L, we established ST2L short hairpin RNA
(shRNA)-expressing P29 cells (shST2L #1 and #2; Figure 5a).
These ST2L knockdown cells were refractory to
rIL-33-induced cell death in GlucL medium (Figure 5b). P29
cells transfected with MyD88 small-interfering RNA (siRNA)
also displayed resistance to rIL-33 (Figures 5c and d).
Because P29 cells secreted sST2 (Figure 5e), we examined
the role of sST2. sST2 knockdown by shRNA augmented the
observed rIL-33-enhanced cell death (Figures 5e and f).
Furthermore, an anti-ST2 antibody suppressed the observed
cell death enhanced by rIL-33 (Figure 5g). These results
indicate that IL-33 augments the death of P29 cells via ST2L
under GlucL conditions.
Figure 1 Expression of ST2 in human normal lung tissues and lung cancers. (A) ST2 expression in lung adenocarcinomas (C) and in the adjacent normal lung tissues (N)
based on the Hou29 and Bhattacharjee30 lung data sets in Oncomine database (Compendia Bioscience, Ann Arbor, MI, USA). (B) Correlation between ST2 expression and
relapse-free survival, and overall survival in lung cancer patients. The data are based on the Okayama lung data set in PrognoScan database (http://www.prognoscan.org).
(C) IL-33 expression in lung adenocarcinomas of different cancer stages based on the Okayama lung data set in Oncomine database. (D) Correlation between IL-33 expression
and overall survival in lung cancer patients. The data are based on the Okayama lung data set in PrognoScan database. (E) Immunofluorescence staining of surfactant protein C
(SP-C) and IL-33 in HLAEpiC cells. The nuclei were counterstained with DAPI. (a) Negative control (NC) for (b). Second antibody only; (b) SP-C. (c) NC for (d). (d) IL-33. Scale
bars, 50 μm. (F) qRT-PCR analysis of the expression of ST2L-related molecules in HLAEpiC cells and in human adenocarcinoma A549 cells. *Po0.05; **Po0.002;
***Po0.0001. (G) RT-PCR analysis of the expression of IL-33/ST2L-related genes in human lung cancer cell lines. Adenocarcinomas: A549, PC-9 and PC-14 cells; squamous
carcinoma: QG56, PC-1 and PC-10 cells; small-cell lung carcinoma: QG90 and PC-6 cells; bronchoalveolar cancer: H358 cells
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IL-33 stimulated signalling pathways that promote cell
death. To gain insight into the mechanism underlying
IL-33-enhanced cell death, we investigated IL-33 signalling in
P29 cells. We found that incubating P29 cells in GlucL or Gln−
medium quickly resulted in the phosphorylation of p38 MAPK
and JNK but not of p44/42 MAPK, IκB-α or Akt (Figure 6a;
Supplementary Figure 8a). The addition of rIL-33 enhanced the
phosphorylation of p38 MAPK and JNK, and IκB-α in P29 cells.
Interestingly, rIL-33 quickly inhibited AMP-activated protein
kinase-α (AMPKα) phosphorylation and enhanced mammalian
target of rapamycin (mTOR) S2448 phosphorylation at later
time points (Figure 6b; Supplementary Figure 8b). rIL-33
did not affect p38 MAPK phosphorylation in A11 cells
(Supplementary Figure 8c). Notably, mTOR phosphorylation
was inhibited by the mTOR inhibitor rapamycin but not by the
p38 MAPK inhibitor SB203580 (Figure 6c), indicating that p38
MAPK is not upstream of mTOR.
To determine which signalling pathway is important for the
observed IL-33-enhanced cell death, we treated P29 cells
with various inhibitors under GlucL or Gln− conditions. In
both cases, SB203580 and rapamycin attenuated the
death-enhancing effect of rIL-33 (Figure 6d; Supplementary
Figure 8d). These results indicate that the activation of
both p38 MAPK and mTOR is essential for inducing P29 cell
Figure 2 Expression of functional ST2L in the low-metastatic, but not in the high-metastatic, 3LL cells. (a) Western blot analysis of ST2L, IL-1RAcP and MyD88 protein
expression. β-Actin served as the loading control. (b) Immunofluorescent staining of ST2L, IL-1RAcP and MyD88. Scale bars, 50 μm. The nuclei were counterstained with DAPI.
(c) Activation of IL-33/ST2L signalling molecules in IL-33-treated P29 cells. P29 cells were treated with 100 ng/ml rIL-33 for the indicated times. β-Actin served as the loading
control. *Note that rapid and transient IkB-α reduction was repeatedly observed after the rIL-33 treatment; the reason for this is unknown. See also Figure 6a and Supplementary
Figure S4. (d) RT-PCR analysis of the mRNA expression of NF-κB target genes in IL-33-treated P29 cells. P29 cells were treated with 100 ng/ml rIL-33 for the indicated times.
Thioglycollate-elicited mouse peritoneal macrophages (Mϕ) were used as the control. (e) In vitro growth of P29 cells cultured in the presence or absence of rIL-33 (100 ng/ml) in
the regular medium. (f) Invasive ability of P29 cells treated with rIL-33 (100 ng/ml) for 2 days. The number of invaded cells per field is shown (n= 6). Bars, S.D. Western blot
images (a and c) have been cropped for presentation. Uncropped images are provided in Supplementary Figure 16
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death. The JNK inhibitor SP600125 and the Iκ-B inhibitor
BAY11-7082 slightly augmented the effect of rIL-33 under
both conditions (Figure 6d; Supplementary Figure 8d),
suggesting roles for JNK and NF-κB activation in cell
survival. The phosphatidylinositol 3ʹ-kinase inhibitor wortman-
nin had no effect.
Figure 3 IL-33 content and IL-33-positive cells in P29 subcutaneous tumours. (a) IL-33 content in the lysates of normal tissues (liver, lung and spleen; n= 3), A11 tumour
tissues (n= 5) and P29 tumour tissues (n= 5). Bars, S.D. (b) IL-33 content in P29 tumour tissues established in B6-wild-type and in IL-33− /−mice. (c) IL-33-positive cells in P29
tumours. Cryosections of P29 and A11 tumours were stained with the goat anti-IL-33 antibody followed by Alexa Fluor 488-conjugated chicken anti-goat IgG. The nuclei were
counterstained with DAPI. The arrows show the cells with cytoplasmic and nuclear IL-33 staining. Scale bars, 50 μm. (d) The number of IL-33-positive cells per field (1 mm2) in
P29 tumour tissues established in B6-wild-type and in IL-33− /−mice. n= 20. (e) The effect of various cytokines on IL-33 expression in P29 and A11 cells. The cells were treated
with vehicle alone, rIL-33 (10 ng/ml), rIL-1β (10 ng/ml), rIL-4 (10 ng/ml), rIL-6 (10 ng/ml), rIFN-γ (10 ng/ml), rTNF-α (10 ng/ml) and rTRAIL (10 ng/ml) for 2 days. Total RNA was
isolated and subjected to qRT-PCR. Bars: SD; *Po0.002; **Po0.0002; ***Po0.0001. (f) Effect of rIL-1β on IL-33 mRNA expression in P29 cells. P29 cells were treated with
rIL-1β at various concentrations for 2 days (left) or at 10 ng/ml for up to 3 days (right). Total RNAwas isolated and subjected to qRT-PCR analysis. (g) Expression of the cytokines
in P29 tumours. The peripheral (P), middle (M) and central (C) regions of P29 tumours established in B6-wild-type and in IL-33− /−mice were resected, and the total RNA isolated
from each region was subjected to qRT-PCR. Bars, S.D.
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IL-33 primarily induced programmed oncosis in P29 cells
under nutrient-depleted conditions. The cultivation of P29
cells in GlucL medium significantly induced apoptosis
compared with A11 cells, as assessed by caspase-3
activation and the increase in the sub-G1 population
(Supplementary Figures 9a and b), consistent with our
previous observation.36 However, rIL-33 addition marginally
increased caspase-3 activity and the sub-G1 population in
P29 and A11 cells (Supplementary Figures 9a and c),
indicating that IL-33 only slightly affected apoptosis.
Accordingly, the pan-caspase inhibitor zVAD-fmk was inef-
fective at reversing the rIL-33-enhanced cell death in P29
cells in both GlutL and Gln− medium (Figure 7a). The
necroptosis inhibitor necrostatin-1 did not ameliorate the cell
death-enhancing effect of rIL-33 (Figure 7b). Furthermore,
rIL-33 addition did not further stimulate the conversion of
LC-3I to LC-3II, which is a marker of autophagy, in P29 or
A11 cells under GlucL or Gln− conditions (Figure 7c). Notably,
the increase in the number of cells with cytoplasmic blisters
and karyolysis, which are unique morphological features of
Figure 4 Enhancement of the cell death of the low-metastatic cells, but not the high-metastatic cells, after treatment with rIL-33 in nutrients-depleted medium and under
hypoxic conditions. Cell viability was evaluated using the trypan blue exclusion (TBE) test unless otherwise indicated. (a) The low-metastatic (P29 and P34) and the high-
metastatic (D6 and A11) cells were treated with rIL-33 (100 ng/ml) for 42 h in glucose-depleted (0.1 g/l; GlucL) medium. (b) P29 and A11 cells were treated with various
concentrations of rIL-33 for 42 h in GlucL medium. (c) P29 and A11 cells were treated with rIL-33 (100 ng/ml) for various periods in GlucL medium. (d) P29 cells were treated with
rIL-33 (100 ng/ml) for 42 h in medium containing various concentrations of glucose (0–0.4 g/l). (e) P29 cells were treated with rIL-33 (100 ng/ml) for 42 h in GlucL medium. Cell
viability was assessed by TBE test, MTT assay and clonogenic assay (Clono). (f) P29, P34, D6 and A11 cells were treated with rIL-33 (100 ng/ml) for 28 h in Gln− medium.
(g) P29 cells were treated with rIL-33 (100 ng/ml) for 28 h in Gln− medium. Cell viability was assessed as described in (e). (h) P29 and A11 cells were treated with rIL-33
(100 ng/ml) for 42 h under hypoxic (1% O2) or anoxic (o0.1% O2) conditions. (i) P29 cells were treated with rIL-33 (100 ng/ml) for 42 h under FBS-depleted (0–0.5%; FBSL)
conditions. Bars, S.D.; *Po0.05; **Po0.003; ***Po0.001
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oncosis,37 was remarkable in rIL-33-treated P29 cells but
not in A11 cells under GlucL (Figures 7d and g) and
Gln− conditions (Supplementary Figure 10).
To examine whether the mitochondria have a role in IL-33-
enhanced cell death, we cultured mitochondrial DNA
(mtDNA)-less ρ0P29 cells, the cybrid P29mtΔ and the control
cybrid P29mtP29 cells, all of which expressed ST2L, sST2,
IL-1AcP andMyD88mRNAs (Supplementary Figures 11a and
b), in GlucL or Gln−medium. Because ρ0P29 and P29mtΔ cells
died shortly after glucose starvation, we could not examine the
effect of rIL-33 (Supplementary Figure 11c). However, these
cells could survive under Gln− conditions. Interestingly, ρ0P29
and P29mtΔ cells were completely refractory to rIL-33,
whereas P29mtP29 cells retained their rIL-33 sensitivity
(Supplementary Figure 11c). rIL-33 neither activated p38
MAPK nor inhibited AMPK-α in ρ0P29 and P29mtΔ cells
(Supplementary Figure 11d). These results indicate that intact
mitochondrial function is required for eliciting the cell death-
enhancing activity of IL-33 in P29 cells.
Because mitochondrial reactive oxygen species (ROS)
overproduction is known to cause cell death,38 we cultured
P29 cells in nutrient-deprived medium in the presence or
absence of rIL-33 and examined ROS production using
H2DCF-DA. When cultured in Gluc
L medium, P29 cells
produced a higher amount of ROS compared with the
untreated cells. However, rIL-33 addition did not stimulate
ROS production further (Figure 7h). Moreover, ROS produc-
tion was unaffected in Gln− medium in P29 cells (Figure 7h).
Similar results were obtained in A11 cells (Supplementary
Figure 12). The antioxidant N-acetylcysteine did not affect
rIL-33-enhanced cell death (Figure 7i). Thus, these results
exclude ROS as a cause of rIL-33-enhanced cell death.
Collectively, on the basis of the facts that triggering ST2L
followed by activating p38 MAPK and mTOR and intact
mitochondria are required for IL-33-enhanced cell death,
which is characterised by cellular blisters and karyolysis, we
conclude that IL-33 enhances the ‘programmed oncosis’37 of
P29 cells under nutrient-depleted conditions.
IL-1β enhances the death of P29 cells under nutrient-
depleted conditions partly through IL-33 induction. As
mentioned above, IL-1β induces IL-33 expression in P29 cells
(Figures 3e and f). Coinciding with these data, rIL-1β-treated
P29 cells expressed and secreted IL-33 protein to a greater
extent than untreated cells (Supplementary Figure 13a). This
result suggested the possibility that IL-1β also enhances P29
cell death under nutrient-depleted conditions via IL-33
production. As expected, rIL-1β decreased the survival of
P29 cells in GlucL medium, and, importantly, addition of the
anti-IL-33 antibody in the medium weakened the death-
enhancing activity of rIL-1β (Supplementary Figures 13b and
c). These data indicate that IL-1β-induced IL-33 acts to
enhance P29 cell death in an autocrine manner.
P29 cells proliferated rapidly in IL-33− /− mice. To inves-
tigate the physiological meaning of the small but consistent
Figure 5 Involvement of ST2L in the IL-33-enhanced cell death of P29 cells. The cells were cultured for 38 h in the presence or absence of rIL-33 (100 ng/ml) in glucose-
depleted (0.1 g/l; GlucL) medium. Cell viability was evaluated using the trypan blue exclusion test. (a) RT-PCR analysis of ST2L mRNA expression in P29 cells stably expressing
control shRNA (shCont) and ST2L shRNA (shST2L #1 and #2). β-Actin (ACTB) served as the control. (b) Sensitivity of shCont, shST2L #1 and shST2L #2 cells to rIL-33 (100 ng/
ml). (c) Western blot analysis of the expression of MyD88 protein in P29 cells transiently transfected with control siRNA (siCont) or with MyD88 siRNA (siMyD88). Western blot
images have been cropped for presentation. Uncropped images are provided in Supplementary Figure 16. (d) Sensitivity of siCont and siMyD88 cells to rIL-33 (100 ng/ml).
(e) Secretion of sST2 by P29 cells stably expressing control shRNA or sST2 shRNA. The indicated cells were cultured for 24 h and the amount of sST2 in the conditioned medium
was quantified by ELISA. (f) Sensitivity of shCont and shsST2 cells to rIL-33 (100 ng/ml). (g) Effect of an anti-ST2 antibody on the sensitivity of P29 cells to rIL-33 (100 ng/ml). P29
cells were cultured in the presence of control goat IgG or anti-ST2 antibody (1 μg/ml). Bars, S.D. *Po0.04; **Po0.01; ***Po0.001. NS, not significant
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enhancement of programmed oncosis in P29 cells by IL-33
under nutrient-depleted conditions, we subcutaneously
injected P29 cells and A11 cells into B6 and IL-33− /− mice,
and monitored tumour growth. We found that P29 tumours
tended to show a faster growth rate in IL-33− /− mice than in
B6 mice, whereas A11 tumours grew at comparable rates
(Figure 8a). Interestingly, P29 tumours in B6 mice had more
haemorrhagic necrosis in the centre of the tumour mass
compared with the tumours in IL-33− /− mice (Figure 8b).
Further supporting these results, ST2L shRNA-expressing
P29 cells also tended to form larger tumours than the control
cells in B6 mice (Figures 8c and d). No difference in the
microvessel density was observed between P29 tumours in
B6 mice and those tumours in IL-33− /− mice (Supplementary
Figure 14a and b). P29 cells seldom metastasised to the
lungs even in IL-33− /− mice, and A11 cells metastasised
comparably in both B6 and IL-33− /− mice (Supplementary
Figure 14c).
IL-33 facilitates high-metastatic cell selection under
in vitro conditions mimicking the tumour microenviron-
ment. To understand the role of IL-33 in the tumours
composed of low- and high-metastatic cells, we cultured a
1 : 1 mixture of EGFP-P29 and DsRed2-A11 cells under
severe conditions (glucose depleted, hypoxic and serum
depleted; GlucL/H/FBSL), similar to those that would be
generated in the tumour microenvironment. P29 cells
exhibited higher rates of cell death than A11 cells when
these cells were cultured for 3 days. rIL-33 further augmented
the death of P29 cells but not of A11 cells (Figures 8e and f).
After an additional 2 days of culture under normal conditions
(recovery), selective survival of DsRed-A11 cells was
observed in the presence of rIL-33 (Figures 8e and f). These
results indicate that IL-33 selects for highly metastatic,
ST2L-negative A11 cells in the tumour microenvironment.
Discussion
In the present study, we found that ST2 expression was
significantly downregulated in lung cancer tissues, irrespec-
tive of histological types, compared with normal lung tissues.
HPAEpiCs expressed ST2L, whereas A549 cells hardly
expressed ST2L. The low-metastatic 3LL cell lines (P29 and
P34 cells) expressed functional ST2L, whereas, quite inter-
estingly, the high-metastatic 3LL cell lines (D6 and A11 cells)
did not. These data suggest that constitutive ST2L expression
might confer a phenotypic disadvantage to lessmalignant lung
cancer cells for growth and survival in vivo.
Our data demonstrated that IL-33 was abundantly
expressed in P29 tumour tissues. A11 tumour tissues
Figure 6 Analysis of IL-33/ST2L signalling pathways involved in IL-33-enhanced P29 cell death. (a–c) Western blot analysis of the effect of IL-33 on the phosphorylation of
signalling molecules in P29 cells. P29 cells were cultured with rIL-33 (100 ng/ml) in glucose-depleted (0.1 g/l; GlucL) medium for the indicated times (a and b) or for 1 h (c). β-Actin
served as the loading control. (d) Effect of various inhibitors on rIL-33-enhanced cell death. P29 cells were cultured with rIL-33 (100 ng/ml) in GlucL medium for 42 h with
SB203580 (20 μM), SP600125 (20 μM), wortmannin (10 μM), BAY11-7082 (5 μM) or rapamycin (1 μM). Vehicle (DMSO) was added to the control culture. Cell viability was
evaluated using the trypan blue exclusion test. Bars; S.D.; *Po0.005: **Po0.002. NS, not significant. Western blot images (a–c) have been cropped for presentation. Uncropped
images are provided in Supplementary Figure 16
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contained a very low level of IL-33, which is in accordance with
the observation that more malignant human lung cancers
express lower levels of IL-33 (Supplementary Figure 2). To our
surprise, we detected IL-33 even in P29 tumours established
in IL-33− /− mice, even though P29 cells hardly expressed
IL-33 in vitro. Indeed, immunostaining for IL-33 showed the
presence of scattered positive cells in P29 tumours in both B6
and IL-33− /− mice. Because TAMs, CAFs, lymphocytes and
tumour endothelial cells were negative for IL-33, we hypothe-
sised that P29 cells themselves were induced to express a
higher level of IL-33 by some kinds of factors in vivo. We found
that, among the cytokines examined, IL-1β induced IL-33
expression to the highest extent in P29 cells in vitro.
Interestingly, we also found that IL-1β-treated P29 cells
secreted IL-33, and that extracellular IL-33 could enhance
IL-33 expression in P29 cells. Both IL-1β and IL-33 were
abundantly present in P29 tumours. Therefore, these cyto-
kines are likely to be involved in the IL-33 expression in P29
cells in vivo. Why IL-33-positive cells exist in scattered cells in
P29 tumours is presently unknown, but may be due to local
concentrations of such IL-33-inducing factors.
Under conditions mimicking the tumour microenvironment,
we observed a significant decrease in cell viability exclusively
in the low-metastatic cells after rIL-33 treatment. Under GlucL
Figure 7 Induction of oncosis in IL-33-treated P29 cells under glucose-depleted conditions. (a) Effect of zVAD-fmk on rIL-33-induced cell death. P29 cells were treated with or
without zVAD-fmk (10 μM) in the presence or absence of rIL-33 (100 ng/ml) under GlucL or Gln− conditions for 42 or 28 h, respectively. Bars, S.D.; *Po0.002. (b) Effect of
necrostatin-1 on rIL-33-induced cell death. P29 cells were treated with or without necrostatin-1 (Nec-1; 10 μM) in the presence or absence of rIL-33 (100 ng/ml) in GlucL medium
or in Gln− medium for 42 or 28 h, respectively. Bars, S.D. *Po0.002. (c) Conversion of LC3-I to LC3-II. P29 and A11 cells were incubated in the presence or absence of rIL-33
(100 ng/ml) under GlucL or Gln− conditions for 42 or 28 h, respectively. (d) Appearance of cells with cytoplasmic blisters. P29 and A11 cells were treated with or without rIL-33
(100 ng/ml) for 40 h in glucose-depleted (0.1 g/l; GlucL) medium. Arrows and arrowheads indicate the cells with blisters and those cells with blebs, respectively. Scale bars,
50 μm. (e) Percentage of cells with cytoplasmic blisters. P29 cells were treated with or without rIL-33 (100 ng/ml) for 36 h in GlucL medium. Bars, S.D. *Po0.002. (f) Appearance
of the cells with karyolysis. P29 and A11 cells were treated with or without rIL-33 (100 ng/ml) for 42 h in GlucL medium. The nuclei were stained with DAPI. Arrows and arrowheads
indicate cells with karyolysis and with apoptotic nuclei, respectively. Scale bars, 100 μm (white); 5 μm (yellow). (g) Percentage of cells with karyolysis. P29 cells were treated with
or without rIL-33 (100 ng/ml) for 36 or 42 h in GlucL medium. Bars, S.D. *Po0.002. (h) Effect of rIL-33 on ROS production in P29 cells. P29 cells were cultured with or without
rIL-33 (100 ng/ml) in GlucL or Gln− medium for 30 or 20 h, respectively. ROS production was measured by flow cytometry after staining the cells with H2DCF-DA. (i) Effect of
N-acetylcysteine (NAC) on rIL-33-induced cell death. P29 cells were cultured with rIL-33 (100 ng/ml) in the presence or absence of NAC (10 mM) for 42 h. *Po0.003. NS, not
significant
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conditions, rIL-33 stimulated the phosphorylation of p38
MAPK, JNK and IκB-α, and suppressed AMPKα phosphoryla-
tion in P29 cells, leading to the enhancement of downstream
mTOR phosphorylation. Likewise, rIL-33 enhanced p38
MAPK activity and suppressed AMPKα activity under Gln−
conditions. The decrease in cell viability was diminished by
SB203580 and by rapamycin. These results clearly indicate
that both the p38MAPK and the AMPKα–mTOR pathways are
required for IL-33 activity.
The results indicated that the mode of cell death enhanced
by rIL-33 did not involve apoptosis, autophagic cell death or
necroptosis. Notably, close examination of the cell morphology
of rIL-33-treated P29 cells under GlucL and Gln− conditions
revealed a conspicuous increase in the number of cells with
cytoplasmic blisters and karyolysis. Moreover, rIL-33 affected
neither cell death nor the phosphorylation of p38 MAPK and
AMPKα in ρ0P29 cells and in P29mtΔ cells under GlucL and/or
Gln− conditions, indicating that intact mitochondria were
required for IL-33-enhanced cell death. These observations
are consistent with the characteristics of oncosis that are
related to energy depletion, leading to the impairment of ionic
pumps in the cell membrane and, in contrast to, apoptosis,
plasma membrane blebbing, karyolysis and organelle-free
cytoplasmic blister formation.37 Oncosis has been considered
a nonprogrammed or accidental type of cell death charac-
terised by swelling.39 However, our findings indicate that the
cell death-enhancing effect of IL-33 under the nutrient-
deprivation conditions is probably due to ‘programmed
oncosis’.
As expected, P29 cells formed smaller primary tumourswith
an increase in necrotic regions in B6 mice than in IL-33− /−
mice, irrespective of the similar vessel density. Coinciding with
this finding, P29 cells lacking ST2L expression had a faster
growth rate than the control cells in B6 mice. These results
indicate that the IL-33/ST2L axis in P29 cells confers a
disadvantage for in vivo tumour growth, supporting the in vitro
results. Although the differencewas small, most likely because
IL-33 enhances P29 cell death only in nutrient-starved and
hypoxic regions in tumours, these results indicate the
physiological role of IL-33 in tumour growth.
Finally, we examined whether A11 cells outgrew in amixture
of A11 and P29 cells after culturing these cells in the presence
of rIL-33 under severe in vitro conditions mimicking the tumour
microenvironment. Consequently, we found that this culture
condition caused A11 cell selection after the exposure/
recovery process. Notably, these results are consistent with
our previous observation that A11 cells outgrew in hypoxic and
naturally nutrient-starved regions in tumours established from
an equal mixture of P29 and A11 cells.36
In summary, our findings demonstrate that IL-1β, in concert
with other unknown co-stimulating factors, induces IL-33 in
ST2L-positive low-metastatic lung cancer cells. IL-33 secreted
by the cells or released as an alarmin by the necrotic cells
enhances the programmed oncosis of the low-metastatic
cells in moderately nutrient-starved and hypoxic regions.
Figure 8 IL-33 suppresses P29 tumour growth and stimulates A11 selection under conditions mimicking the tumour microenvironment. (a) Tumour growth of P29 and
A11 cells in B6-wild-type and in IL-33− /− mice. P29 and A11 cells (1 × 105 cells) were subcutaneously injected into B6-wild-type (B6) and IL-33− /− (KO) mice. n= 7. Bars, S.D.
(b) Gross observation of P29 tumours established by P29 cells in B6-wild-type and IL-33− /− mice. The tumours were divided into two equal portions, and the divided faces are
shown. (c) RT-PCR analysis of the expression of ST2L and sST2 in P29 cells stably expressing control shRNA (shCont) and ST2 shRNA (shST2 #2). (d) shCont and shST2 #2
cells (4 × 105 cells) were subcutaneously injected in B6 mice. n= 7. Bars, S.D. (e) Effect of rIL-33 on A11 cell selection. A 1 : 1 mixture of EGFP-P29 and DsRed-A11 cells was
cultured with or without rIL-33 (100 ng/ml) for 3 days under GlucL/H/FBSL conditions and then for an additional 2 days in regular medium (recovery). Bars, S.D. *Po0.01;
**Po0.001. NS, not significant. (f) rIL-33 stimulation of an A11 selection under conditions mimicking the tumour microenvironment. A 1 : 1 mixture of EGFP-P29 and DsRed-A11
cells was cultured as described in (e). The cells were observed under a confocal laser microscope. Bars, 100 μm
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IL-1β-induced IL-33 is also involved in enhancing the death of
P29 cells. ST2L-negative high-metastatic lung cancer cells
are unsusceptible to IL-33. Consequently, IL-33 provides a
selective pressure for ST2L-negative, oncosis-resistant cells,
which may expand after HIF-1-dependent translocation to the
proximal regions of tumour blood vessels,40 thus increasing
the ratio of malignant cells (Supplementary Figure 15).
Although we cannot currently examine this possibility in
human lung cancers because cell lines expressing functional
ST2L have not yet been identified, the inhibition of this process
by an anti-IL-33 antibody or sST2 may provide a clue for
possible treatments to suppress the malignant progression of
lung cancers.
Materials and Methods
Cells and cell culture. HPAEpiCs purchased from ScienCell (Carlsbad, CA,
USA) were cultured in alveolar epithelial cell medium supplemented with 2% foetal
bovine serum (FBS), epithelial cell growth supplement and penicillin/streptomycin.
The characteristics of low-metastatic (P29 and P34) and high-metastatic (D6 and
A11) cells established from 3LL were described previously.36,41–43 mtDNA-less
ρ0 P29 cells, and the cybrid P29mtΔ and P29mtP29 cells that were established by
reintroducing mtDNA with a large-scale deletion (3696 bp) and wild-type mtDNA into
ρ0P29 cells, respectively, were generated as described previously.43,44 Human
adenocarcinoma A549, PC-9 and PC-14 cells; squamous carcinoma QG56, PC-1
and PC-10 cells; small-cell lung carcinoma QG90 and PC-6 cells; and
bronchoalveolar cancer H358 cells were supplied by the Chiba Cancer Centre.45
These cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% FBS and 50 μg/ml gentamicin at 37 °C in a humidified atmosphere
of 5% CO2 in air. The cells were also cultured in glucose-depleted
(0.1–0.4 g/l; GlucL), glutamine-deprived (Gln−) or serum-depleted (0.5%; FBSL)
culture medium or under hypoxic (1% O2) or anoxic (o0.1% O2) conditions.
Reagents and antibodies. Recombinant mouse IL-33 (rIL-33) and
recombinant mouse ST2L/IL-1 R4 Fc chimaera (rsST2L-Fc) were purchased from
R&D Systems, Inc. (McKinley Place NE, MN, USA). Human IL-1β (IL-1β), human
IL-4 (IL-4), human IL-6 (IL-6), human IFN-γ, human TNF-α and human TRAIL
(TRAIL) were purchased from PeproTech (Rocky Hill, NJ, USA). Matrigel was
obtained from Invitrogen (Life Technologies, Carlsbad, CA, USA). SB205580,
SP600125, wortmannin and rapamycin were supplied by Calbiochem (San Diego,
CA, USA). BAY11-7082 and necrostatin-1 were obtained from Sigma-Aldrich
(St. Louis, MO, USA). The antibodies used for western blotting, immunocytochem-
istry and immunohistochemistry are listed in Supplementary Table I.
Intracellular ROS measurement. The cells were incubated with 5 μM
2′,7′-dichlorodihydrofluorescein diacetate (H2DCF-DA; Molecular Probes, Life
Technologies) for 10 min, washed once with Dulbecco’s phosphate-buffered saline
(DPBS) and immediately subjected to flow cytometry using a FACSCalibur flow
cytometer (BD Biosciences, San Jose, CA, USA).46
Cell viability assay. To examine the effect of rIL-33 on the viability of 3LL
cells, the cells were cultured under various conditions in the presence or absence of
mouse rIL-33 (0–100 ng/ml) for 28 or 42 h. Cell viability was examined by trypan
blue dye exclusion, MTT and clonogenic assays. For the MTT assay, the cells
(2 × 104 cells/100 μl/well of 96-well multiwell plates) were incubated with MTT
(10 μl/well; Sigma-Aldrich) for 4 h at 37 °C. The formazan crystals were dissolved in
100 μl of DMSO with shaking. The absorbance was measured at 550 nm on a plate
reader. For the clonogenic assay, the cells were seeded into a 10-cm dish (100 cells
per dish) and then cultured for 10 days. The numbers of colonies were counted after
fixation in methanol followed by staining with 0.05% crystal violet.
Invasion assay. An invasion assay was performed using Matrigel (30 μg)-
coated, 8-μm pore size FluoroBlok transwell chambers (BD Sciences). FBS (10%)
was added to the lower chamber as a chemoattractant. The detailed protocol is
described elsewhere.46
Western blotting. The cells were extracted with RIPA buffer (50 mM Tris-HCl,
pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% SDS, 2 mM EDTA)
containing cOmplete Protease Inhibitor Cocktail and PhosSTOP Phosphatase
Inhibitor Cocktail (Roche Applied Science, Penzberg, Upper Bavaria, Germany) on
ice for 20 min. The lysates were centrifuged at 10 000xg for 10 min at 4 °C, and the
supernatants were used to estimate the amount of protein with a Bradford
colorimetric assay using bovine serum albumin as the standard. SDS-polyacry-
lamide gel electrophoresis and immunoblot analyses were performed as previously
described.46 The signals were visualised using ECL Plus (GE Healthcare, Little
Chalfont, UK). The membranes were scanned using a luminoimaging analyser
LAS4000 (GE Healthcare). β-Actin was used as the loading control.
Immunocytochemistry. Cells cultured under various conditions were fixed
with 4% formaldehyde, blocked with 3% BSA/0.1% glycine in DPBS, and then
immunostained as previously described.46 The primary antibodies used were goat
anti-IL-33 antibody, goat anti-ST2L antibody, rabbit polyclonal anti-IL-1RAcP
antibody and mouse monoclonal anti-MyD88 antibody. Alexa Fluor 594-
conjugated species-specific secondary antibodies were used. The nuclei were
counterstained with DAPI (1 μg/ml). Then, the slides were mounted with Vectashield
Mounting Medium (Vector Laboratories, Burlingame, CA, USA) and observed under
a confocal laser scanning microscope (Fluoview, Olympus, Tokyo, Japan).
Immunohistochemistry. Tumours were surgically removed, immediately
embedded and frozen in OCT compound. For immunofluorescent staining, cryostat
sections cut at 6 μm were fixed in acetone for 10 min, blocked with 0.1% BSA in
DPBS and then incubated simultaneously with goat polyclonal anti-IL-33 antibody
followed by Alexa Fluor 488- or Alexa Fluor 594-conjugated chicken anti-goat
secondary antibody. The sections were counterstained with DAPI and observed
under a confocal laser scanning microscope (Fluoview).
RNA extraction and RT-PCR analysis. Total RNA extraction with TRIzol
reagent (Sigma-Aldrich) and semiquantitative RT-PCR were performed as described
previously.46 Real-time PCR was performed with cDNA using THUNDERBIRD
SYBR qPCR Mix (TOYOBO, Osaka, Japan) and 0.3 μM primers in a total volume of
20 μl. The reactions were run on a Thermal Cycler Dice Real Time System TP860
(TaKaRa, Shiga, Japan). The PCR protocol consisted of an initial denaturation step
at 95 °C for 1 min and 40 cycles of denaturation (95 °C for 15 s) and extension
(60 °C for 1 min). Dissociation curve analyses were performed to confirm the PCR
product identity and to differentiate specific amplification from non-specific products
by denaturation (95 °C for 15 s), annealing (60 °C for 30 s) and slow heating to
95 °C. The results were evaluated as relative expression levels standardised using
the expression level of GAPDH mRNA. The forward and reverse primers used for
the PCR reactions are listed in Supplementary Table II.
Knockdown by shRNA or by siRNA. For ST2L or sST2 knockdown,
MISSION mouse ST2 shRNA lentiviral vectors (TRCN0000039057:
CCGGCAAAGAGGACGCTCGACTTATCTCGAGATAAGTCGAGCGTCCTCTTTGTT
TTTG, and TRCN0000039056: CCGGGCTCGACTTATCCTGTGGAATCTCGAGA
TTCCACAGGATAAGTCGAGCTTTTTG), both of which target the coding sequence
of ST2 and sST2 mRNA, or sST2 shRNA lentiviral vectors (TRCN0000039054:
CCGGCCAACAGGAATCTCTGTCATTCTCGAGAATGACAGAGATTCCTGTTGGTT
TTTG), which targets only the 3′-UTR of sST2 mRNA, in the pLKO.1-puro plasmid
(Sigma-Aldrich) were used. For the controls, MISSION pLKO.1-puro control
transduction particles (SHC001v) were used. Lentiviral stocks encoding the shRNA
were prepared by transient co-transfection of HEK293T cells with the shRNA-
encoding transfer vector and the MISSION Lentiviral Packaging Mix. P29 cells were
transduced with the lentivirus stocks in the presence of Polybrene (8 μg/ml).
Transduced cells were selected with puromycin (5 μg/ml) to allow for the generation
of the control cells (shCont) or of cells displaying stable ST2L (shST2L) or sST2
(shsST2) downregulation. For the transient knockdown of MyD88, P29 cells were
transfected with 20 nM mouse MyD88 siRNA (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) or Silencer Negative Control #1 siRNA (Ambion, Thermo Fisher
Scientific, Waltham, MA, USA) with Lipofectamine 2000 RNAiMAX reagent
(Invitrogen) according to the manufacturer’s protocol. Two days after transfection,
the cells were subjected to immunoblot analysis and viability assays.
Quantification of sST2 and IL-33. For the quantification of sST2, the cells
were cultured for 24 h, and the conditioned media were collected. The amount of
sST2L was measured using a mouse ST2L/IL-1 R4 Quantikine ELISA kit (R&D
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Systems) according to the manufacturer’s instructions. For the quantification of
IL-33 in tumour tissues, dissected tissues were homogenised in cold DPBS with a
Potter-Elvehjem homogeniser, sonicated and cleared by ultracentrifugation at
45 000xg for 30 min. The resulting supernatant was used to quantify the amount of
IL-33/g of tumour tissue wet weight using a mouse/rat IL-33 Quantikine ELISA kit
(R&D Systems). For the quantification of IL-33 secreted by IL-1β-treated P29 cells,
the cells (1 × 106 cells) were cultured for 3 days, and the conditioned media were
collected and concentrated 10-fold using Amicon Ultracel-3 K (Millipore, Billerica,
MA, USA). IL-1β-treated P29 cells were lysed in RIPA buffer and cleared by
centrifugation at 10 000xg for 20 min. The resulting supernatant was used to
quantify the amount of IL-33 and total protein.
Apoptosis assay. Caspase-3 activation was measured using a caspase-3
assay kit (MBL, Nagoya, Japan). For the measurement of DNA fragmentation, the
cells were detached using trypsin-EDTA, fixed in 70% ethanol for 30 min and then
stained with 50 μg/ml propidium iodide in phosphate-citrate buffer containing
100 μg/ml RNaseA (Sigma-Aldrich). FACS analysis was performed to detect the
sub-G1 fraction.
Animal experiments. All animal experiments were performed in compliance
with the institutional guidelines for the care and use of laboratory animals. The
protocol was approved by the IZUMO Campus Animal Care and Use Committee of
Shimane University (permission number: IZ26-7). C57BL/6N male mice were
purchased from CLEA Japan, Inc. (Osaka, Japan). C57BL/6N-IL-33− /− mice
(CDB0631K)47 were obtained from RIKEN CDB (Kobe, Japan) (http://www.cdb.
riken.jp/arg/mutant%20mice%20list.html) and inbred at the institutional animal
facility. These mice were maintained under specific pathogen-free conditions at a
controlled temperature of 23± 2 °C, relative humidity 55± 10%, and with a 12-h
light–dark cycle. The mice were intermittently checked for health throughout the
entire experimental period after tumour injection. Mice were killed by CO2 inhalation
at the end of the study.
Assay of tumour growth and metastasis. Seven- to 11-week-old
C57BL/6N (B6) wild-type mice and C57BL/6N-IL-33− /− mice were subcutaneously
injected with 2 × 105 P29 or A11 cells in 100 μl of DMEM. Tumour sizes were
measured using callipers, and the tumour volumes were calculated using the
formula, ab2/2, where a and b are the lengths of the long and short axes,
respectively. The number of metastases was evaluated by counting the parietal
nodules in the lungs after fixation in Bouin’s solution.
Statistical analysis. All data are presented as the mean±S.D. Statistical
significance between data sets was tested by unpaired Student’s t-test. Po0.05
was considered significant.
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